Announcement on the Capital Increase of Shanghai North Carolina by Subsidiary Peak Pharmaceutical
Release time:
2020-08-05
证券代码:600668 证券简称:尖峰集团 公告编号:临2018-025
债券简称:13尖峰02 债券代码:122344
浙江尖峰集团股份有限公司
关于子公司尖峰药业对上海北卡增资的公告
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。
重要内容提示:
l拟增资的控股子公司名称:上海北卡医药技术有限公司
l拟增资金额:5000万元
l出资方式:拟使用自筹资金进行增资
一、对外投资概述
(一)2018年8月3日,本公司控股子公司浙江尖峰药业有限公司(以下简称:尖峰药业)和自然人吴江与康立涛、李倩、郑亚玲及上海北卡医药技术有限公司(以下简称:上海北卡)签订《股权增资协议》,对尖峰药业的控股子公司上海北卡进行增资,增资价格:以坤元资产评估有限公司所出具了《资产评估报告》(坤元评报〔2017〕1-37号)为基础,以2018年1月19日尖峰药业与各方签订的《关于上海北卡医药技术有限公司之增资和股权转让协议》中约定的增资价格为准,确定为:每1元注册资本的认缴价格为11.53元。尖峰药业出资人民币5000万元,自然人吴江出资人民币1000万元,上海北卡的其他股东放弃参与本次增资。
增资完成后,上海北卡注册资本由原来的1755.55万元增加至2275.93万元,其中尖峰药业占61.48%,康立涛占18.42%,李倩占11.46%,郑亚玲4.83%,吴江3.81%。
(二)董事会审议情况
2018年8月3日,公司以通讯方式召开了第十届董事会第五次会议,公司现有九名董事,全部参加了会议,经审议与表决,董事会以9票同意、0票反对、0票弃权审议并通过了该事项。
(三)根据上海证券交易所《股票上市规则》和公司《章程》等有关规定,公司本次对外投资属董事会权限范围,无需提交股东大会审议。该股权收购事项不属于关联交易,也不构成《上市公司重大资产重组管理办法》规定的重大资产重组情况。
二、新增股东的基本情况
吴江,男,中国国籍,住址:浙江省东阳市吴宁街道东岘新村**幢*号,职业:安徽众望董事长兼总经理。
三、投资标的基本情况
(一)上海北卡的基本情况
1、企业名称:上海北卡医药技术有限公司
2、企业性质:有限责任公司
3、注册地:上海市松江区申港路3802号21幢
4、注册日期:2003年10月20日
5、主要办公地点:上海市松江区申港路3802号21幢
6、法定代表人:蒋晓萌
7、注册资本:1755.55万元
8、经营范围:医药和化学专业技术领域内的技术开发、技术咨询、技术服务、技术转让;机械设备、仪器仪表、食用农产品(不含生猪产品)、化肥、饲料添加剂、化工原料及产品(除危险品)批发零售;医药中间体的开发、销售;从事货物及技术的进出口业务。(依法须经批准的项目,经相关部门批准后方可开展经营活动)
9、股东情况
2018年1月,本公司控股子公司尖峰药业与有关各方签订了协议,以收购股权和增资的方式对上海北卡进行投资。详见本公司于2018年1月20日《关于子公司尖峰药业对外投资的公告》。2018年5月,尖峰药业完成了该投资事宜,上海北卡完成了工商变更登记手续,成为尖峰药业的控股子公司。
|
序号 |
股东名称 |
出资额(万元) |
出资比例(%) |
|
1 |
浙江尖峰药业有限公司 |
965.55 |
55.00 |
|
2 |
康立涛 |
419.26 |
23.88 |
|
3 |
李倩 |
260.74 |
14.85 |
|
4 |
郑亚玲 |
110.00 |
6.27 |
|
|
合计 |
1755.55 |
100.00 |
(二)标的公司2017年和2018年半年度财务报表情况
截至2017年末,上海北卡合并资产总额8801.80万元、负债总额7435.37万元、归属于母公司股东权益1366.43万元;2017年合并营业收入9296.47万元、归属于母公司所有者净利润-475.45万元;
截至2018年6月末,上海北卡合并资产总额12828.90 万元、负债总额3346.36万元、归属于母公司股东权益9482.54万元。2018年1-6月合并营业收入8505.53万元、归属于母公司所有者净利润557.63万元。
2017年度的财务数据经具有证券、期货从业资格的天健会计师事务所(特殊普通合伙)审计,2018年半年度的财务数据未经审计。
四、合作协议的主要内容
尖峰药业(甲方1)和吴江(甲方2)(合称甲方)、上海北卡(乙方或标的公司)和原股东康立涛、李倩、郑亚玲(合称丙方)签订了《关于上海北卡医药技术有限公司之增资协议》。协议的主要内容有:
(一)股权增资方案
1.增资价格
三方同意,本次增资的价格以2018年1月19日甲方1和丙方、海南寰太生物医药产业创业投资基金合伙企业、乙方签订的《关于上海北卡医药技术有限公司之增资和股权转让协议》中约定的增资价格为准,本协议项下的增资价格为:每1元注册资本的认缴价格为11.53元。
2.甲方增资金额
2.1本协议项下,甲方1本次增资额为人民币5000万元。其中,433.65万元记入注册资金,4566.35万元记入资本公积。
甲方2本次增资额为人民币1000万元。其中,86.73万元记入注册资金,913.27万元记入资本公积。
2.2本次增资完成后,乙方的注册资本由1755.55万元增加至2275.93万元,甲方1持有乙方61.48%股权、甲方2持有乙方3.81%股权。
3. 本次增资后乙方的股权结构变化
本次增资完成后,乙方的股东持股比例及出资情况如下:
|
股东名称 |
出资额(万元) |
持有比例(%) |
出资方式 |
|
浙江尖峰药业有限公司 |
1399.20 |
61.48 |
货币 |
|
康立涛 |
419.26 |
18.42 |
货币 |
|
李倩 |
260.74 |
11.46 |
货币 |
|
郑亚玲 |
110.00 |
4.83 |
货币 |
|
吴江 |
86.73 |
3.81 |
货币 |
|
合计 |
2275.93 |
100.00 |
|
4.增资款
本协议项下的增资款,由甲方于本协议生效后的30个工作日内一次性支付至乙方指定的验资账户。
5.股份转让限制
甲2同意,通过协议转让等方式出让公司股份时,视同为“原个人股东”,共同遵守《关于上海北卡医药技术有限公司之增资和股权转让协议》(2018年1月19日签署)的约定。
6.反稀释条款
各方约定,在甲方投资入股后五年内,若乙方公司进行后续增资,其增资价格不得低于甲方本轮增资的价格。
(二)增资手续办理
1. 本协议正式签署之前或当日,乙方应召开股东会,审议本次股权增资事宜。
2. 增资款到位后的30个工作日内,乙方应完成增资的全部法律手续,包括但不限于变更股东名册、修改公司章程、办理工商变更登记手续等。
(三)违约责任
若任何一方违反本协议的约定,给守约方造成实际损失或者丧失投资/融资机会,守约方可要求违约方赔偿经济损失。
(四)争议解决
因本协议所引起的或与本协议有关的任何争议,应协商解决,协商不成的,任何一方都可将争议提交金华市仲裁委员会,根据该会仲裁规则在金华市进行仲裁。
(五)协议的生效、变更与解除
1.本协议的生效需同时满足如下条件:
1.1本协议经协议各方自然人本人或法人的法定代表人签字并盖章;
1.2乙方股东会审议通过本次增资事宜。
1.3甲1的有权部门通过本次增资事宜。
五、本次增资对公司的影响
(一)本次合作是公司加强医药业务板块发展的具体实施,本次增资有利于提升上海北卡的综合实力,增加上海北卡的资金流,为其收购安徽众望制药有限公司提供资金保障。
(二)本次对外投资的资金来源为公司的自筹资金。
(三)本次对外投资对公司当期利润不会造成重大影响。
六、备查文件
公司第十届董事会第五次会议决议
特此公告。
浙江尖峰集团股份有限公司董事会
2018年8月3日
More information
2020
11-03
Jinhua Municipal Party Committee Secretary Chen Long: I wish your enterprise better and better
On the morning of October 16, Chen long, secretary of the Jinhua Municipal CPC Committee, and his entourage came to the construction site of Jianfeng Pharmaceutical's internationalization project to investigate and affirmed the good development status and clear future development ideas of Jianfeng Pharmaceutical. At the construction site, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, introduced the overall situation of the investment scale, factory layout, and production direction of the Jianfeng Pharmaceutical internationalization project to Chen Long and his entourage. Huang Jinlong, general manager of the pharmaceutical company, accompanied Chen Long and his entourage to visit the preparation workshop under construction. The construction site is neat, tidy and orderly, and the facilities and equipment are perfect and advanced, all have been unanimously affirmed by the leaders who came to investigate. When learning that the peak internationalization project has introduced international advanced equipment, built in accordance with European and American standards, and its products are oriented to the international market, Chen long said happily: "your goals are very clear and your thinking is very clear. I wish your enterprise better and better!" (this newspaper reporter)
2020
10-23
Liu Haiping, vice mayor of Pu'er City, said during the survey: "Peak is an enterprise with feelings"
On September 30, Liu Haiping, member of the standing Committee of the Pu'er Municipal CPC Committee and vice mayor of Pu'er City, Yunnan Province, and relevant responsible persons of Pu'er City and Simao District, visited the company for investigation and research, and communicated with the leaders of the group company on topics such as further strengthening cooperation between the two sides. "Yunnan Jianfeng has not only developed well in Pu'er these years, achieved good benefits and contributed considerable tax revenue, but also made great contributions to promoting the economic development of Pu'er and the stability of the southwest border region. It is our 'star enterprise' and 'baby enterprise '." Liu Haiping said so in the exchange. He said that Pu'er is an important window for the implementation of the "Belt and Road" concept. It has good conditions in natural resources, transportation, electricity, etc., and the peak is a "sentimental enterprise" and has a good foundation in the local area. Strengthen cooperation; various government departments will also earnestly "stand on the platform" and "do a good job as a shopkeeper" to serve enterprises. Chairman Jiang Xiaomeng and General Manager Yu Jianhong exchanged views with Liu Haiping and his party on the layout of peak industry and strengthening cooperation with Pu 'er. After that, accompanied by General Manager Yu Jianhong and Deputy General Manager Huang Jinlong, Liu Haiping and his party visited the Jinxi Factory of Jianfeng Pharmaceutical Factory. (this newspaper reporter)
2020
10-09
The first batch of Jianfeng Pharmaceuticals to enter Jinhua (Shanghai) Science and Technology Center
News from our newspaper On September 16, at the unveiling ceremony of the Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Innovation Center and Jinhua (Shanghai) Talent Building, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, took over from Chen Long, secretary of the Jinhua Municipal Party Committee. The golden key with big red flowers. Spike Pharmaceuticals became one of the first seven companies to enter the center. The Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Center and Jinhua (Shanghai) Talent Building are the first "Science and Technology and Talent Enclave" in Shanghai in the nine cities of the Yangtze River Delta G60 Science and Technology Corridor, and the first cross-regional industrial collaborative innovation center in the Science and Technology Corridor. The center is located in Shanghai Lingang Songjiang Science and Technology City, with a total area of nearly 10,000 square meters. It includes two parts: science and technology innovation and talent service. There are five major centers, including talent service center, science and technology innovation exhibition center, business incubation center, enterprise research and development center, and talent project roadshow center. It is a science and technology innovation platform that integrates the functions of project incubation, recruitment of institutions, and talent recruitment. Chen Long, secretary of the Jinhua Municipal Party Committee, said in his speech at the unveiling ceremony that in the future, all scientific and technological enterprises stationed in Jinhua (Shanghai) Science and Technology Center and Talent Building can equally enjoy Jinhua's local science and technology and talent policies, so as to further break the space limitation, enable talents from the two places to share the most favorable treatment and convenient services, help enterprises to develop in Shanghai and achieve industrialization in Jinhua. At the ceremony, leaders such as Chen Long, secretary of the Jinhua Municipal Party Committee, and Cheng Xiangmin, secretary of the Shanghai Songjiang District Party Committee, awarded seven companies, including Jianfeng Pharmaceutical, the golden key to symbolize their entry. At the Yangtze River Delta Integrated Talent Cooperation Project Symposium held after the ceremony, Jiang Xiaomeng spoke as a representative of Jinhua entrepreneurs. He believed that Shanghai, as an international metropolis, has an agglomeration effect on high-end intellectual resources and grasps the first-class element resources of scientific and technological innovation in China and even the world. The establishment of G60 Jinhua (Shanghai) science and technology innovation center and talent building in the Yangtze River Delta helps Jinhua enterprises to take off in scientific and technological innovation and information exchange, which will provide strong and continuous scientific and technological support and intellectual support for the long-term development of enterprises in the future, and attract more excellent domestic and foreign talents to serve Jinhua enterprises, It plays a key role in further improving scientific research ability, innovation ability and personnel training. During the event, Jiang Xiaomeng successively accepted on-site interviews with "People's Daily", "Liberation Daily", "Zhejiang Daily" and other media. He said that the establishment of science and technology innovation and talent bases in Shanghai has greatly enhanced Jinhua's attractiveness to enterprises. "With this base, we don't need to introduce talents to Jinhua, but directly recruit talents in Shanghai, and at the same time enjoy Jinhua's various talent recruitment policies, and change Shanghai talents to Jinhua's use. This is a kind of bold. The innovation has greatly solved the dilemma of attracting talents for enterprises." As a settled enterprise, it will also make full use of its own advantages to continuously inject resource vitality into the science and technology innovation center, and continue to contribute to the long-term development of Jinhua's economy. (this newspaper reporter)
2020
09-22
Spike Pharmaceutical Added New Products
On September 3, Spike Pharmaceutical Company received the approval of the State Drug Administration for the registration of esomeprazole sodium for injection (approval number: 2020S00572). Esomeprazole sodium for injection is mainly used to treat low-risk patients with gastroesophageal reflux disease and acute gastric or duodenal ulcer bleeding when oral therapy is not applicable. It has been listed in the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List (2017 Edition) ", classified as Class B. According to industry statistics, 30 companies including Zhengda Tianqing and Qilu Pharmaceutical have been approved for listing in China. In 2019, domestic sales (including urban and county-level public hospitals, community and township health centers) were about 3.317 billion yuan. Jianfeng Pharmaceutical submitted an application for registration of esomeprazole sodium for injection to the State Food and Drug Administration in November 2013 and was accepted. Up to now, Jianfeng Pharmaceutical has invested nearly 15 million yuan in research and development for the project and has a corresponding production line. This time to obtain the injection of esomeprazole sodium drug registration approval, marking the peak pharmaceutical has the drug production, sales qualification, will further enrich the peak pharmaceutical product line, help to enhance the competitiveness of the peak pharmaceutical business. (Lu Yating, Liu Yang)
2020
09-11